In situ self-assembling Au-DNA complexes for targeted cancer bioimaging and inhibition

Maonan Wang(State Key Laboratory of Digital Medical Engineering), Yun Chen(State Key Laboratory of Digital Medical Engineering), Weijuan Cai(State Key Laboratory of Digital Medical Engineering), Huan Feng(State Key Laboratory of Digital Medical Engineering), Tianyu Du(State Key Laboratory of Digital Medical Engineering), Weiwei Liu(State Key Laboratory of Digital Medical Engineering), Hui Jiang(State Key Laboratory of Digital Medical Engineering), A. Pasquarelli(Universität Ulm), Yossi Weizmann(Ben-Gurion University of the Negev), Xuemei Wang(State Key Laboratory of Digital Medical Engineering)
Proceedings of the National Academy of Sciences
December 16, 2019
Cited by 74Open Access
Full Text

Abstract

Cancer remains one of the most challenging diseases to treat. For accurate cancer diagnosis and targeted therapy, it is important to assess the localization of the affected area of cancers. The general approaches for cancer diagnostics include pathological assessments and imaging. However, these methods only generally assess the tumor area. In this study, by taking advantage of the unique microenvironment of cancers, we effectively utilize in situ self-assembled biosynthetic fluorescent gold nanocluster-DNA (GNC-DNA) complexes to facilitate safe and targeted cancer theranostics. In in vitro and in vivo tumor models, our self-assembling biosynthetic approach allowed for precise bioimaging and inhibited cancer growth after one injection of DNA and gold precursors. These results demonstrate that in situ bioresponsive self-assembling GNC-PTEN (phosphatase and tensin homolog) complexes could be an effective noninvasive technique for accurate cancer bioimaging and treatment, thus providing a safe and promising cancer theranostics platform for cancer therapy.


Related Papers